Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 501

Results For "ED"

9539 News Found

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion
Drug Approval | August 03, 2024

European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept


Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL
Drug Approval | August 03, 2024

Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL

Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia


Supriya Lifescience names Dr. Saloni Wagh as MD
People | August 03, 2024

Supriya Lifescience names Dr. Saloni Wagh as MD

Shivani Satish Wagh takes on the role of Joint Managing Director


Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
News | August 03, 2024

Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr

EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin


Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr
News | August 02, 2024

Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr

Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore


GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
News | August 02, 2024

GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr

Strong topline growth driven by solid performance across key brands.


Lupin receives approval from USFDA for Emtricitabine and Tenofovir Alafenamide Tablets
Drug Approval | August 01, 2024

Lupin receives approval from USFDA for Emtricitabine and Tenofovir Alafenamide Tablets

This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries


Dr. Agarwals Eye Hospital posts standalone Q1 FY25 PAT higher at Rs. 14.11 Cr
News | August 01, 2024

Dr. Agarwals Eye Hospital posts standalone Q1 FY25 PAT higher at Rs. 14.11 Cr

Dr. Agarwals Eye Hospital has reported total income of Rs. 100.42 crores during the period ended June 30, 2024


DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control
Policy | August 01, 2024

DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control

More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options


Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr
News | August 01, 2024

Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr

The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY